<DOC>
	<DOCNO>NCT00410306</DOCNO>
	<brief_summary>This observational study drug call Nebido , new testosterone replacement therapy , available treatment male hypogonadism . The benefit safety Nebido already thoroughly evaluate well controlled clinical trial . The main purpose observational study confirm establish safety profile Nebido daily clinical practice .</brief_summary>
	<brief_title>Use Nebido® Assess Tolerability Treatment Outcomes Daily Clinical Practice</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male hypogonadal patient eligible longterm testosterone therapy newly prescribe Nebido® accordance term market authorization Patients present contraindication state product information</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Nebido</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Observational Study</keyword>
</DOC>